| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (1994) 33, 685-706
© 1994 The British Society for Antimicrobial Chemotherapy
review-article |
Structure-activity and structure-side-effect relationships for the quinolone antibacterials
Department of Chemistry, Parke-Davis Pharmaceutical Research Division of Warner-Lambert Company 2800 Plymouth Road, Ann Arbor, MI 48105, USA
Received 21 July 1993; accepted 17 September 1993
The fluoroquinolones represent a major class of antibacterials with great therapeutic potential. Over the years, several structure-activity and side-effect relationships have been developed, covering thousands of analogues, in an effort to improve overall antimicrobial efficacy while reducing undesirable side-effects. In this review, the various structural features of the quinolones which govern antibacterial efficacy and influence the side-effect profile are delineated and summarized at the molecular level. Those features which most remarkably enhance antimicrobial effectiveness are: a halogen (F or Cl) at the 8-position which improves oral absorption and activity against anaerobes; an alkylated pyrrolidine or piperazine at C7 which increases serum half-life and potency vs Gram-positive bacteria; and a cyclopropyl group at N1 and an amino substituent at C5, both of which improve overall potency. Some side-effects of the quinolones are class effects, and cannot be modulated by molecular variation. These include gastrointestinal irritation and arthropathy. Several other potential side-effects are directly influenced by structural modification. For example, CNS effects and drug interactions with theophylline and NSAIDs are strongly influenced by the C7 substituent with simple pyrrolidines and piperazines the worst actors. Increasing steric bulk through alkylation ameliorates these effects. Phototoxicity is determined by the nature of the 8-position substituent with halogen causing the greatest photo reaction while hydrogen and methoxy show little light induced toxicity. Genetic toxicity is controlled in additive fashion by the choice of groups at the 1, 7 and 8 positions. From the analysis, those groups which mutually improve efficacy while reducing side-effects are identified. In addition, preclinical models for determining potential side-effects are discussed.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. M. Attia Abatement by naringin of lomefloxacin-induced genomic instability in mice Mutagenesis, November 1, 2008; 23(6): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J Mehlhorn and D. A Brown Safety Concerns with Fluoroquinolones Ann. Pharmacother., November 1, 2007; 41(11): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Witte, U. Plappert, H. de Wall, and A. Hartmann Genetic Toxicity Assessment: Employing the Best Science for Human Safety Evaluation Part III: The Comet Assay as an Alternative to In Vitro Clastogenicity Tests for Early Drug Candidate Selection Toxicol. Sci., May 1, 2007; 97(1): 21 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Krishna, J. C. Kisicki, S. Olsen, D. M. Grasela, and Z. Wang The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers J. Clin. Pharmacol., May 1, 2007; 47(5): 628 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Capparelli, M. D. Reed, J. S. Bradley, G. L. Kearns, R. F. Jacobs, B. D. Damle, J. L. Blumer, and D. M. Grasela Pharmacokinetics of Gatifloxacin in Infants and Children Antimicrob. Agents Chemother., March 1, 2005; 49(3): 1106 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yabe, H. Satoh, Y. Ishii, T. Jindo, T. Sugawara, K. Furuhama, M. Goryo, and K. Okada Early Pathophysiologic Feature of Arthropathy in Juvenile Dogs Induced by Ofloxacin, a Quinolone Antimicrobial Agent Vet. Pathol., November 1, 2004; 41(6): 673 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K Yoo, D. M Triller, C.-S. Yong, and T. P Lodise Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections Ann. Pharmacother., July 1, 2004; 38(7): 1226 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hayashi, Y. Nakata, and A. Yazaki New Findings on the Structure-Phototoxicity Relationship and Photostability of Fluoroquinolones with Various Substituents at Position 1 Antimicrob. Agents Chemother., March 1, 2004; 48(3): 799 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hayakawa, Y. Fukushima, H. Kato, H. Fukumoto, T. Kadota, H. Yamamoto, H. Kuroiwa, J. Nishigaki, and A. Tsuji METABOLISM AND DISPOSITION OF NOVEL DES-FLUORO QUINOLONE GARENOXACIN IN EXPERIMENTAL ANIMALS AND AN INTERSPECIES SCALING OF PHARMACOKINETIC PARAMETERS Drug Metab. Dispos., November 1, 2003; 31(11): 1409 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Noble, F. M. Barnard, and A. Maxwell Quinolone-DNA Interaction: Sequence-Dependent Binding to Single-Stranded DNA Reflects the Interaction within the Gyrase-DNA Complex Antimicrob. Agents Chemother., March 1, 2003; 47(3): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ince, X. Zhang, L. C. Silver, and D. C. Hooper Dual Targeting of DNA Gyrase and Topoisomerase IV: Target Interactions of Garenoxacin (BMS-284756, T-3811ME), a New Desfluoroquinolone Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3370 - 3380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Perrone, K. C. Takahashi, and G. M. Williams Inhibition of Human Topoisomerase II{alpha} by Fluoroquinolones and Ultraviolet A Irradiation Toxicol. Sci., September 1, 2002; 69(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Lawrence, M. Frosco, B. Ryan, S. Chaniewski, H. Yang, D. C. Hooper, and J. F. Barrett Bactericidal Activities of BMS-284756, a Novel Des-F(6)-Quinolone, against Staphylococcus aureus Strains with Topoisomerase Mutations Antimicrob. Agents Chemother., January 1, 2002; 46(1): 191 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. A. Weller, J. M. Andrews, G. Jevons, and R. Wise The in vitro activity of BMS-284756, a new des-fluorinated quinolone J. Antimicrob. Chemother., January 1, 2002; 49(1): 177 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gargallo-Viola, S. Ferrer, E. Tudela, M. Robert, R. Coll, R. Roser, and J. Guinea Antibacterial Activities and Pharmacokinetics of E-4767 and E-5065, Two New 8-Chlorofluoroquinolones with a 7-Azetidin Ring Substituent Antimicrob. Agents Chemother., November 1, 2001; 45(11): 3113 - 3121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hartman-Neumann, K. DenBleyker, L. A. Pelosi, L. E. Lawrence, J. F. Barrett, and T. J. Dougherty Selection and Genetic Characterization of Streptococcus pneumoniae Mutants Resistant to the Des-F(6) Quinolone BMS-284756 Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2865 - 2870. [Abstract] [Full Text]
|
|
|
|
|
|
E. J. Randinitis, J. R. Koup, G. Rausch, R. Abel, N. J. Bron, N. J. Hounslow, A. B. Vassos, and A. J. Sedman Clinafloxacin Pharmacokinetics in Subjects with Various Degrees of Renal Function Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2536 - 2542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Randinitis, C. W. Alvey, J. R. Koup, G. Rausch, R. Abel, N. J. Bron, N. J. Hounslow, A. B. Vassos, and A. J. Sedman Drug Interactions with Clinafloxacin Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2543 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Lawrence, P. Wu, L. Fan, K. E. Gouveia, A. Card, M. Casperson, K. Denbleyker, and J. F. Barrett The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues J. Antimicrob. Chemother., August 1, 2001; 48(2): 195 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Siami, N. Christou, I. Eiseman, K. J. Tack, and the Clinafloxacin Severe Skin And Soft Tissue Infe Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections Antimicrob. Agents Chemother., February 1, 2001; 45(2): 525 - 531. [Abstract] [Full Text]
|
|
|
|
|
|
M. Wainwright Acridine--a neglected antibacterial chromophore J. Antimicrob. Chemother., January 1, 2001; 47(1): 1 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kang, L. Wang, X.-L. Chen, D. J. Triggle, and D. Rampe Interactions of a Series of Fluoroquinolone Antibacterial Drugs with the Human Cardiac K+ Channel HERG Mol. Pharmacol., January 1, 2001; 59(1): 122 - 126. [Abstract] [Full Text]
|
|
|
|
|
|
M. D. Cubbon and R. G. Masterton New quinolones--a fresh answer to the pneumococcus J. Antimicrob. Chemother., December 1, 2000; 46(6): 869 - 872. [Full Text] [PDF]
|
|
|
|
|
|
D. Ince and D. C. Hooper Mechanisms and Frequency of Resistance to Premafloxacin in Staphylococcus aureus: Novel Mutations Suggest Novel Drug-Target Interactions Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3344 - 3350. [Abstract] [Full Text]
|
|
|
|
|
|
R. Gozalbes, M. Brun-Pascaud, R. García-Domenech, J. Gálvez, P.-M. Girard, J.-P. Doucet, and F. Derouin Prediction of Quinolone Activity against Mycobacterium avium by Molecular Topology and Virtual Computational Screening Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2764 - 2770. [Abstract] [Full Text]
|
|
|
|
|
|
R. Gozalbes, M. Brun-Pascaud, R. Garcia-Domenech, J. Galvez, P.-M. Girard, J.-P. Doucet, and F. Derouin Anti-Toxoplasma Activities of 24 Quinolones and Fluoroquinolones In Vitro: Prediction of Activity by Molecular Topology and Virtual Computational Techniques Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2771 - 2776. [Abstract] [Full Text]
|
|
|
|
|
|
K. Shimoda, T. Ikeda, S. Okawara, and M. Kato Possible Relationship between Phototoxicity and Photodegradation of Sitafloxacin, a Quinolone Antibacterial Agent, in the Auricular Skin of Albino Mice Toxicol. Sci., August 1, 2000; 56(2): 290 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ball Quinolone generations: natural history or natural selection? J. Antimicrob. Chemother., July 1, 2000; 46(90003): 17 - 24. [Abstract] [Full Text]
|
|
|
|
|
|
A. De Sarro, V. Cecchetti, V. Fravolini, F. Naccari, O. Tabarrini, and G. De Sarro Effects of Novel 6-Desfluoroquinolones and Classic Quinolones on Pentylenetetrazole-Induced Seizures in Mice Antimicrob. Agents Chemother., July 1, 1999; 43(7): 1729 - 1736. [Abstract] [Full Text]
|
|
|
|
|
|
A. Delon, S. Bouquet, F. Huguet, V. Brunet, P. Courtois, and W. Couet Pharmacokinetic-Pharmacodynamic Contributions to the Convulsant Activity of Fluoroquinolones in Rats Antimicrob. Agents Chemother., June 1, 1999; 43(6): 1511 - 1515. [Abstract] [Full Text]
|
|
|
|
 |
|
 H.-G. Wetzstein, M. Stadler, H.-V. Tichy, A. Dalhoff, and W. Karl Degradation of Ciprofloxacin by Basidiomycetes and Identification of Metabolites Generated by the Brown Rot Fungus Gloeophyllum striatum Appl. Envir. Microbiol., April 1, 1999; 65(4): 1556 - 1563. [Abstract] [Full Text]
|
|
|
|
|
|
J. M. Entenza, J. Vouillamoz, M. P. Glauser, and P. Moreillon Efficacy of Trovafloxacin in Treatment of Experimental Staphylococcal or Streptococcal Endocarditis Antimicrob. Agents Chemother., January 1, 1999; 43(1): 77 - 84. [Abstract] [Full Text]
|
|
|
|
|
|
A. Delon, C. Pariat, P. Courtois, S. Bouquet, and W. Couet A New Approach for Early Assessment of the Epileptogenic Potential of Quinolones Antimicrob. Agents Chemother., October 1, 1998; 42(10): 2756 - 2758. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Tokura, N. Seo, H. Yagi, F. Furukawa, and M. Takigawa Cross-Reactivity in Murine Fluoroquinolone Photoallergy: Exclusive Usage of TCR V{beta}13 by Immune T Cells That Recognize Fluoroquinolone-Photomodified Cells J. Immunol., April 15, 1998; 160(8): 3719 - 3728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Delon, F. Huguet, P. Courtois, J.-M. Vierfond, S. Bouquet, and W. Couet Pharmacokinetic-Pharmacodynamic Contributions to the Convulsant Activity of Pefloxacin and Norfloxacin in Rats J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 983 - 987. [Abstract] [Full Text]
|
|